Compare Alcon AG (ALC) vs Aterian Inc (ATER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Aterian Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Aterian Inc trades at $1.22 (market cap $13.25M). The key difference: Alcon AG is far larger — about 2467.2× Aterian Inc's market cap, and Alcon AG pays a 0.54% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ALC | ATER | |
|---|---|---|
Market Cap | $32.69B | $13.25M |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $1.55 |
52-Week Low | $62.02 | $0.54 |
Enterprise Value | $36.28B | $13.83M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Aterian (ATER) trades at $1.24, down 3.12% today, with a bullish technical signal from moving averages. The company shows improving operational trends with three consecutive quarterly earnings beats, though it remains unprofitable with a -30.78% net margin. Recent news highlights a special stockholders meeting on July 10, 2026, to vote on proposals that could return $0.85–$1.14 per share.
Investment outlook is mixed: positive technical momentum and potential shareholder returns contrast with persistent losses and negative cash flow. Key risks include sustained unprofitability and high short interest growth of 57.7% in March 2026. Analysts are evenly split between Buy and Hold ratings, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →
